Premium
What is the outcome in patients with acute leukaemia who survive severe acute graft‐versus‐host disease?
Author(s) -
Ringdén O.,
Labopin M.,
Sadeghi B.,
Mailhol A.,
Beelen D.,
Fløisand Y.,
Ghavamzadeh A.,
Finke J.,
Ehninger G.,
Volin L.,
Socié G.,
Kröger N.,
Stuhler G.,
Ganser A.,
Schmid C.,
Giebel S.,
Mohty M.,
Nagler A.
Publication year - 2018
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/joim.12695
Subject(s) - medicine , hematopoietic stem cell transplantation , disease , complication , graft versus host disease , transplantation
Background Acute graft‐versus‐host disease ( aGVHD ) is a major complication of allogeneic haematopoietic stem cell transplantation ( HSCT ). With new promising therapies, survival may improve for severe aGVHD . Objectives We wanted to analyze the long‐term outcome in patients who survive severe aGVHD . Methods This study was a landmark analysis of 23 567 patients with acute Leukaemia who survived for more than 6 months after HSCT , 2002–2014. Patients alive after severe aGVHD ( n = 1738) were compared to controls. Results Patients with severe aGVHD had higher non‐relapse mortality ( NRM ) and higher rate of extensive chronic GVHD ( cGVHD ) than the controls ( P < 10 −5 ). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia‐free survival ( LFS ) and overall survival were significantly lower than for the controls ( P < 10 −5 ). Five‐year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD. Conclusions HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD , a higher NRM , a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD.